Oxford BioDynamics (AIM:OBD) described challenges and progress as the AIM-listed diagnostics group reported revenue of £0.69 million for the six months to 31 March 2026, up from £0.59 million a year earlier, while operating losses narrowed to £4.68 million from £5.88 million.
Cash and term deposits stood at £2.51 million at the period end, falling to £1.38 million by 31 May.
Sales of EpiSwitch PSE, its prostate screening test, reached 1,788 in the half-year, up 66% on the second half of 2025 and 126% on the prior-year period. OBD said more than 5,000 PSE tests have now been sold since launch, with over half of those in the current financial year.
The company also appointed Richard Compton as chief executive with immediate effect. Compton was previously senior vice president of sales and commercial operations at Oxford Nanopore Technologies, where OBD said annual revenue grew from around £4 million to more than £200 million during his tenure. Chairman Iain Ross, executive chairman since January 2025, will remain as non-executive chairman.
Alongside the results, OBD said it had signed MK Commercial Group to expand its US physician-facing sales effort. The partnership will initially deploy seven field-based consultants across markets including New Jersey, Washington DC, Virginia, Georgia and Chicago, with capacity to scale to 35 representatives. The group is also in commercial discussions with three large pharma companies for EpiSwitch Orion and is targeting commercial availability of its ME/CFS blood test before the end of 2026.
